author-photo

Larisa Ryvo

Tel Aviv Sourasky Medical Center

25

Papers

603

Citations

Citation Trend

Filter By

Papers (23) Sort By

Journal Conference Others

Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with CNS Involvement from the NALA Trial

2021 Oncologist
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PD13-09: Impact of neratinib on outcomes in HER2-positive metastatic breast cancer patients with central nervous system disease at baseline: Findings from the phase 3 NALA trial

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Abstract PS9-02: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.

2021 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (0)
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (218)
Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC)

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (24)
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial

2018 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (24)
Abstract P1-07-14: Real-life analysis evaluating >1000 N0/N1mi estrogen receptor (ER)+ breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score (RS) result: Clinical outcomes with median follow up of > 9 years

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry

2017
Show All
- Source
- Cite
- Save
Citations (40)
245PDDuration of response and tumor shrinkage with first-line ribociclib + letrozole in postmenopausal women with HR+, HER2– ABC

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)